3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
4
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Carcinoma, Renal Cell
5
Relapsed Pediatric Solid Tumor
2
Ovarian Neoplasms
2
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Kidney Neoplasms
1
Endometrial Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Breast Neoplasms
1
Interventions
Thyroidectomy
4
Iodine-131
4
trametinib
3
dabrafenib
3
apatinib
3
anlotinib
2
Surgical Procedures, Operative
2
Blood Specimen Collection
2
Biopsy, Large-Core Needle
2
toripalimab
1
tislelizumab
1
surufatinib
1
regorafenib
1
penpulimab
1
pembrolizumab
1
pazopanib
1
palbociclib
1
olaparib
1
lenvatinib
1
famitinib
1
camrelizumab
1
Ultrasonography
1
Thyroxine
1
Thyrotropin Alfa
1
Sunitinib
1
Second Harmonic Generation Microscopy
1
Routinely Collected Health Data
1
Rosiglitazone
1
Robotic Surgical Procedures
1
Radiotherapy, Intensity-Modulated
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Thyroid Neoplasms
×
pazopanib
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled